Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

The $2 per pack increase is projected to help 32,400 adults quit smoking, keep 7,000 youth from taking it up, and generate ...